Haugeberg G, Uhlig T, Falch JA, Halse JI, Kvien TK (2000) Reduced bone mineral density in male rheumatoid arthritis patients: frequencies and associations with demographic and disease variables in ninety-four patients in the Oslo County Rheumatoid Arthritis Register. Arthritis Rheum 43:2776–2784

Article  CAS  PubMed  Google Scholar 

Haugeberg G, Uhlig T, Falch JA, Halse JI, Kvien TK (2000) Bone mineral density and frequency of osteoporosis in female patients with rheumatoid arthritis: results from 394 patients in the Oslo County Rheumatoid Arthritis register. Arthritis Rheum 43:522–530

Article  CAS  PubMed  Google Scholar 

Tanaka S (2019) RANKL is a therapeutic target of bone destruction in rheumatoid arthritis. F1000Res 8:F1000 Faculty Rev-533

Delgado-Calle J, Sato AY, Bellido T (2017) Role and mechanism of action of sclerostin in bone. Bone 96:29–37

Article  CAS  PubMed  Google Scholar 

Terpos E, Fragiadaki K, Konsta M, Bratengeier C, Papatheodorou A, Sfikakis PP (2011) Early effects of IL-6 receptor inhibition on bone homeostasis: a pilot study in women with rheumatoid arthritis. Clin Exp Rheumatol 29:921–925

PubMed  Google Scholar 

McClung MR, Grauer A, Boonen S, Bolognese MA, Brown JP, Diez-Perez A, Langdahl BL, Reginster JY, Zanchetta JR, Wasserman SM, Katz L, Maddox J, Yang YC, Libanati C, Bone HG (2014) Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med 370:412–420

Article  CAS  PubMed  Google Scholar 

Gennari L, Rotatori S, Bianciardi S, Nuti R, Merlotti D (2016) Treatment needs and current options for postmenopausal osteoporosis. Expert Opin Pharmacother 17:1141–1152

Article  CAS  PubMed  Google Scholar 

Kobayakawa T, Miyazaki A, Kanayama Y, Hirano Y, Takahashi J, Suzuki T, Nakamura Y (2023) Comparable efficacy of denosumab and romosozumab in patients with rheumatoid arthritis receiving glucocorticoid administration. Mod Rheumatol 33:96–103

Article  PubMed  Google Scholar 

Orimo H, Nakamura T, Hosoi T, Iki M, Uenishi K, Endo N, Ohta H, Shiraki M, Sugimoto T, Suzuki T, Soen S, Nishizawa Y, Hagino H, Fukunaga M, Fujiwara S (2012) Japanese 2011 guidelines for prevention and treatment of osteoporosis–executive summary. Arch Osteoporos 7:3–20

Article  PubMed  PubMed Central  Google Scholar 

Genant HK, Wu CY, van Kuijk C, Nevitt MC (1993) Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 8:1137–1148

Article  CAS  PubMed  Google Scholar 

Lewiecki EM, Binkley N, Morgan SL, Shuhart CR, Camargos BM, Carey JJ, Gordon CM, Jankowski LG, Lee JK, Leslie WD (2016) Best practices for dual-energy X-ray absorptiometry measurement and reporting: International Society for Clinical Densitometry Guidance. J Clin Densitom 19:127–140

Article  PubMed  Google Scholar 

Ebina K, Hirao M, Hashimoto J, Matsuoka H, Iwahashi T, Chijimatsu R, Etani Y, Okamura G, Miyama A, Yoshikawa H (2018) Impact of switching oral bisphosphonates to denosumab or daily teriparatide on the progression of radiographic joint destruction in patients with biologic-naive rheumatoid arthritis. Osteoporos Int 29:1627–1636

Article  CAS  PubMed  Google Scholar 

Nenonen A, Cheng S, Ivaska KK, Alatalo SL, Lehtimaki T, Schmidt-Gayk H, Uusi-Rasi K, Heinonen A, Kannus P, Sievanen H, Vuori I, Vaananen HK, Halleen JM (2005) Serum TRACP 5b is a useful marker for monitoring alendronate treatment: comparison with other markers of bone turnover. J Bone Miner Res 20:1804–1812

Article  CAS  PubMed  Google Scholar 

Ebina K, Etani Y, Tsuboi H, Nagayama Y, Kashii M, Miyama A, Kunugiza Y, Hirao M, Okamura G, Noguchi T, Takami K, Goshima A, Miura T, Fukuda Y, Kurihara T, Okada S, Nakata K (2022) Effects of prior osteoporosis treatment on the treatment response of romosozumab followed by denosumab in patients with postmenopausal osteoporosis. Osteoporos Int 33:1807–1813

Article  CAS  PubMed  Google Scholar 

Harre U, Georgess D, Bang H, Bozec A, Axmann R, Ossipova E, Jakobsson PJ, Baum W, Nimmerjahn F, Szarka E, Sarmay G, Krumbholz G, Neumann E, Toes R, Scherer HU, Catrina AI, Klareskog L, Jurdic P, Schett G (2012) Induction of osteoclastogenesis and bone loss by human autoantibodies against citrullinated vimentin. J Clin Invest 122:1791–1802

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wysham KD, Shofer J, Lui G, Trupin L, Andrews JS, Black DM, Graf J, Shoback DM, Katz PP (2022) Low cumulative disease activity is associated with higher bone mineral density in a majority Latinx and Asian US rheumatoid arthritis cohort. Semin Arthritis Rheum 53:151972

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gulyas K, Horvath A, Vegh E, Pusztai A, Szentpetery A, Petho Z, Vancsa A, Bodnar N, Csomor P, Hamar A, Bodoki L, Bhattoa HP, Juhasz B, Nagy Z, Hodosi K, Karosi T, FitzGerald O, Szucs G, Szekanecz Z, Szamosi S, Szanto S (2020) Effects of 1-year anti-TNF-alpha therapies on bone mineral density and bone biomarkers in rheumatoid arthritis and ankylosing spondylitis. Clin Rheumatol 39:167–175

Article  PubMed  Google Scholar 

Hamar A, Szekanecz Z, Pusztai A, Czokolyova M, Vegh E, Petho Z, Bodnar N, Gulyas K, Horvath A, Soos B, Bodoki L, Bhattoa HP, Nagy G, Tajti G, Panyi G, Szekanecz E, Domjan A, Hodosi K, Szanto S, Szucs G, Szamosi S (2021) Effects of one-year tofacitinib therapy on bone metabolism in rheumatoid arthritis. Osteoporos Int 32:1621–1629

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kabata D, Ayumi S (2019) Statistical analysis of observational study. J Japan Soc Pain Clin 26:1–6

Google Scholar 

Kanda Y (2013) Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant 48:452–458

Article  CAS  PubMed  Google Scholar 

Nagayama Y, Ebina K, Tsuboi H, Hirao M, Hashimoto J, Yoshikawa H, Okada S, Nakata K (2022) Low serum albumin concentration is associated with increased risk of osteoporosis in postmenopausal patients with rheumatoid arthritis. J Orthop Sci 27:1283–1290

Article  PubMed  Google Scholar 

Mochizuki T, Yano K, Ikari K, Hiroshima R, Okazaki K (2023) Comparison of romosozumab versus denosumab treatment on bone mineral density after 1 year in rheumatoid arthritis patients with severe osteoporosis: a randomized clinical pilot study. Mod Rheumatol 33:490–495

Article  PubMed  Google Scholar 

Yeremenko N, Zwerina K, Rigter G, Pots D, Fonseca JE, Zwerina J, Schett G, Baeten D (2015) Tumor necrosis factor and interleukin-6 differentially regulate Dkk-1 in the inflamed arthritic joint. Arthritis Rheumatol 67:2071–2075

Article  CAS  PubMed  Google Scholar 

Kaneshiro S, Ebina K, Shi K, Higuchi C, Hirao M, Okamoto M, Koizumi K, Morimoto T, Yoshikawa H, Hashimoto J (2014) IL-6 negatively regulates osteoblast differentiation through the SHP2/MEK2 and SHP2/Akt2 pathways in vitro. J Bone Miner Metab 32:378–392

Article  CAS  PubMed  Google Scholar 

Jung YK, Kang YM, Han S (2019) Osteoclasts in the inflammatory arthritis: implications for pathologic osteolysis. Immune Netw 19:e2

Article  PubMed  PubMed Central  Google Scholar 

Ominsky MS, Libanati C, Niu QT, Boyce RW, Kostenuik PJ, Wagman RB, Baron R, Dempster DW (2015) Sustained modeling-based bone formation during adulthood in cynomolgus monkeys may contribute to continuous BMD gains with denosumab. J Bone Miner Res 30:1280–1289

Article  CAS  PubMed  Google Scholar 

Komori T (2013) Functions of the osteocyte network in the regulation of bone mass. Cell Tissue Res 352:191–198

Article  PubMed  PubMed Central  Google Scholar 

Kashii M, Kamatani T, Nagayama Y, Miyama A, Tsuboi H, Ebina K (2023) Baseline serum PINP level is associated with the increase in hip bone mineral density seen with romosozumab treatment in previously untreated women with osteoporosis. Osteoporos Int 34:563–572

Article  CAS  PubMed  Google Scholar